This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Radiation

Authoring team

Radiation therapy is generally reserved for patients in whom both surgical and medical interventions have not provided biochemical control (1).

  • reduces growth hormone concentrations in 90% of patients

  • prevents regrowth of the tumour in 99%

  • possible complications include:
    • hypopituitarism:
      • commonest side effect
      • about half of patients may require replacement for adrenocorticotrophin hormone, thyroid stimulating hormone, or gonadotrophin deficiency by 10 years
    • visual loss
    • brain necrosis
    • tumorigenesis

Notes:

  • stereotactic radiosurgery techniques have advantages over conventional fractionated radiotherapy
    • better targeting and reduced radiation exposure to surrounding tissue and shorter time to achieve control of IGF-1 and GH levels
    • extremely large tumor volumes or tumors near the chiasm are not amenable to radiosurgery - therefore such cases require fractionated radiotherapy
    • with either fractionated radiotherapy or radiosurgery
      • may take many years to achieve the full therapeutic effect and continued medical treatment will usually be needed.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.